Valuation: Edesa Biotech, Inc.

Market Cap 28.91M 25.93M 23.7M 21.64M 40.76M 2.72B 42.05M 286M 114M 1.45B 109M 106M 4.58B P/E 2026 *
-1.08x
P/E 2027 * -1.04x
Enterprise Value 28.91M 25.93M 23.7M 21.64M 40.76M 2.72B 42.05M 286M 114M 1.45B 109M 106M 4.58B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
86.25%
Yield 2026 *
-
Yield 2027 * -
1 day+0.47%
1 week-16.73%
Current month-16.73%
1 month-42.47%
3 months-57.62%
6 months-85.72%
Current year+50.70%
1 week 2.01
Extreme 2.01
2.61
1 month 2.01
Extreme 2.01
3.96
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
54.99
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 01/08/2015
Director of Finance/CFO 57 01/05/2025
President 48 07/06/2019
Director TitleAgeSince
Chairman 50 07/06/2019
Director/Board Member 55 07/06/2019
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap. Importance
5/10/26 Free

Founder

6,893 0.0510%
1/9/26 Free

Founder

5,714 0.0593%
3/8/26 Free

Founder

5,324 0.0553%
Change 5-day change 1-year change 3-year change Capi.($)
+0.47%-16.73%+25.88%-34.95% 28.91M
-4.83%+3.51%+53.62%+61.75% 65.94B
-1.34%+2.98%+24.79%+100.18% 56.53B
+0.02%+1.07%+10.63%+76.66% 56.88B
+5.09%+9.89%+22.45%+107.48% 46.49B
+2.62%+1.68%+28.91%+37.01% 44.8B
+8.24%+0.51%+213.26%+792.66% 41.59B
-1.86%+10.13%+26.82%+53.22% 35.35B
-2.97%-9.84%+88.86%+76.17% 33.29B
-2.18%+7.06%+36.06%-4.95% 24.92B
Average +0.33%+1.25%+53.13%+126.52% 40.58B
Weighted average by Cap. +0.21%+3.40%+53.12%+142.94%

Financials

2026 *2027 *
Net sales - -
Net income -17.52M -15.72M -14.36M -13.11M -24.71M -1.65B -25.48M -173M -69.04M -879M -65.78M -64.37M -2.77B -23.88M -21.42M -19.57M -17.87M -33.66M -2.24B -34.72M -236M -94.07M -1.2B -89.63M -87.7M -3.78B
Net Debt - -
Projected Income Statement - Annual - Edesa Biotech, Inc.
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
-
Date Price Change Volume
06/11/26 US$2.140 +0.47% 37,766
05/11/26 US$2.130 -1.84% 33,892
04/11/26 US$2.170 -4.82% 43,999
03/11/26 US$2.280 -6.56% 53,260
02/11/26 US$2.440 -5.06% 44,811
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Edesa Biotech, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.140USD
Average target price
16.33USD
Spread / Average Target
+663.24%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Edesa Biotech, Inc.
  1. Stock Market
  2. Stocks
  3. EDSA Stock